Literature DB >> 21828202

Antibodies against aquaporin-4 in neuromyelitis optica: distinction between recurrent and monophasic patients.

Immy A Ketelslegers1, Piet W Modderman, Anke Vennegoor, Joep Killestein, Dörte Hamann, Rogier Q Hintzen.   

Abstract

The detection of antibodies against aquaporin-4 (AQP4) has improved the diagnosis of neuromyelitis optica (NMO). We evaluated a recently established cell-based anti-AQP4 assay in 273 patients with inflammatory CNS demyelination. The assay had a specificity of 99% and a sensitivity of 56% to detect all NMO patients and of 74% to detect the recurrent NMO patients, similar to the initial studies reported. AQP4 antibodies were absent in monophasic NMO patients, while samples in recurrent cases remained positive during follow-up. We conclude that the pathogenesis of monophasic NMO may be different from that of relapsing NMO.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21828202     DOI: 10.1177/1352458511412995

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  11 in total

1.  Evaluation of aquaporin-4 antibody assays.

Authors:  Patrick J Waters; Sean J Pittock; Jeffrey L Bennett; Sven Jarius; Brian G Weinshenker; Dean M Wingerchuk
Journal:  Clin Exp Neuroimmunol       Date:  2014-04-22

2.  Incidence of AQP4-IgG seropositive neuromyelitis optica spectrum disorders in the Netherlands: About one in a million.

Authors:  E Daniëlle van Pelt; Yu Yi M Wong; Immy A Ketelslegers; Dorine Am Siepman; Dörte Hamann; Rogier Q Hintzen
Journal:  Mult Scler J Exp Transl Clin       Date:  2016-01-26

3.  Incidence and outcome of acquired demyelinating syndromes in Dutch children: update of a nationwide and prospective study.

Authors:  C L de Mol; Y Y M Wong; E D van Pelt; I A Ketelslegers; D P Bakker; M Boon; K P J Braun; K G J van Dijk; M J Eikelenboom; M Engelen; K Geleijns; C A Haaxma; J M F Niermeijer; E H Niks; E A J Peeters; C M P C D Peeters-Scholte; B T Poll-The; R P Portier; J F de Rijk-van Andel; J P A Samijn; H M Schippers; I N Snoeck; H Stroink; R J Vermeulen; A Verrips; F Visscher; J S H Vles; M A A P Willemsen; C E Catsman-Berrevoets; R Q Hintzen; R F Neuteboom
Journal:  J Neurol       Date:  2018-03-22       Impact factor: 4.849

4.  The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults.

Authors:  C L de Mol; Yym Wong; E D van Pelt; Bha Wokke; Tam Siepman; R F Neuteboom; D Hamann; R Q Hintzen
Journal:  Mult Scler       Date:  2019-05-16       Impact factor: 6.312

Review 5.  Molecular pathogenesis of neuromyelitis optica.

Authors:  Wajih Bukhari; Michael H Barnett; Kerri Prain; Simon A Broadley
Journal:  Int J Mol Sci       Date:  2012-10-11       Impact factor: 5.923

Review 6.  Update on biomarkers in neuromyelitis optica.

Authors:  Esther Melamed; Michael Levy; Patrick J Waters; Douglas Kazutoshi Sato; Jeffrey L Bennett; Gareth R John; Douglas C Hooper; Albert Saiz; Amit Bar-Or; Ho Jin Kim; Lakha Pandit; Maria Isabel Leite; Nasrin Asgari; Najib Kissani; Rogier Hintzen; Romain Marignier; Sven Jarius; John Marcelletti; Terry J Smith; Michael R Yeaman; May H Han; Orhan Aktas; Metha Apiwattanakul; Brenda Banwell; Denis Bichuetti; Simon Broadley; Philippe Cabre; Tanuja Chitnis; Jerome De Seze; Kazuo Fujihara; Benjamin Greenberg; Kerstin Hellwig; Raffaele Iorio; Sven Jarius; Eric Klawiter; Ingo Kleiter; Marco Lana-Peixoto; Kevin O'Connor; Jacqueline Palace; Friedman Paul; Naraporn Prayoonwiwat; Klemens Ruprecht; Olaf Stuve; Thomas Tedder; Silvia Tenembaum; Juan P Garrahan; Buenos Aires; Katja van Herle; Danielle van Pelt; Pablo Villoslada; Emmanuelle Waubant; Brian Weinshenker; Dean Wingerchuk; Jens Würfel; Scott Zamvil
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-07-23

Review 7.  Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).

Authors:  Corinna Trebst; Sven Jarius; Achim Berthele; Friedemann Paul; Sven Schippling; Brigitte Wildemann; Nadja Borisow; Ingo Kleiter; Orhan Aktas; Tania Kümpfel
Journal:  J Neurol       Date:  2013-11-23       Impact factor: 4.849

8.  Relationship between Azathioprine metabolites and therapeutic efficacy in Chinese patients with neuromyelitis optica spectrum disorders.

Authors:  Xindi Li; Shenghui Mei; Xiaoqing Gong; Heng Zhou; Li Yang; Anna Zhou; Yonghong Liu; Xingang Li; Zhigang Zhao; Xinghu Zhang
Journal:  BMC Neurol       Date:  2017-07-05       Impact factor: 2.474

9.  HLA association in MOG-IgG- and AQP4-IgG-related disorders of the CNS in the Dutch population.

Authors:  Arlette L Bruijstens; Yu Yi M Wong; Daniëlle E van Pelt; Pieter J E van der Linden; Geert W Haasnoot; Rogier Q Hintzen; Frans H J Claas; Rinze F Neuteboom; Beatrijs H A Wokke
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-03-20

10.  Treatment and outcome of aquaporin-4 antibody-positive NMOSD: A multinational pediatric study.

Authors:  Renata Barbosa Paolilo; Yael Hacohen; Elise Yazbeck; Thais Armangue; Arlette Bruijstens; Christian Lechner; Samira Luisa Apostolos-Pereira; Yana Martynenko; Markus Breu; Carolina de Medeiros Rimkus; Evangeline Wassmer; Matthias Baumann; Laura Papetti; Marco Capobianco; Barbara Kornek; Kevin Rostásy; José Albino da Paz; Olga Ciccarelli; Ming Lim; Albert Saiz; Rinze Neuteboom; Romain Marignier; Cheryl Hemingway; Douglas Kazutoshi Sato; Kumaran Deiva
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.